These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17268523)

  • 1. Rituximab in CD20 positive multiple myeloma.
    Moreau P; Voillat L; Benboukher L; Mathiot C; Dumontet C; Robillard N; Hérault O; Garnache F; Garand R; Varoqueaux N; Avet-Loiseau H; Harousseau JL; Bataille R;
    Leukemia; 2007 Apr; 21(4):835-6. PubMed ID: 17268523
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
    Greipp PT; Kapoor P; Morice WG; Witzig TE; Greipp PR
    Leukemia; 2008 Jan; 22(1):214-5. PubMed ID: 17928885
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab in CD20 positive multiple myeloma.
    Bergua JM; Cabrera C; Arteta EG; Prieto J
    Leukemia; 2008 May; 22(5):1082-3. PubMed ID: 17972949
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-CD20 monoclonal antibody therapy in multiple myeloma.
    Kapoor P; Greipp PT; Morice WG; Rajkumar SV; Witzig TE; Greipp PR
    Br J Haematol; 2008 Apr; 141(2):135-48. PubMed ID: 18318769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reply to 'Rituximab activity in CD20-positive multiple myeloma'.
    Gozzetti A; Fabbri A; Lazzi S; Bocchia M; Lauria F
    Leukemia; 2008 May; 22(5):1083; author reply 1083-4. PubMed ID: 17972948
    [No Abstract]   [Full Text] [Related]  

  • 6. [Loss of CD20 expression following rituximab-combined chemotherapy in CD20-positive and CyclinD1-positive multiple myeloma].
    Shiratori S; Kondo T; Kubota K; Wakasa K; Ibata M; Shono Y; Takahata M; Shigematu A; Kato N; Ota S; Tanaka J; Matsuno Y; Asaka M; Imamura M
    Rinsho Ketsueki; 2008 Nov; 49(11):1536-40. PubMed ID: 19047784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy.
    Korte W; Jost C; Cogliatti S; Hess U; Cerny T
    Ann Oncol; 1999 Oct; 10(10):1249-50. PubMed ID: 10586345
    [No Abstract]   [Full Text] [Related]  

  • 8. [Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma].
    Matsuda I; Mori Y; Nakagawa Y; Sawanobori M; Uemura N; Suzuki K
    Rinsho Ketsueki; 2005 Dec; 46(12):1293-7. PubMed ID: 16447802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Resistance to rituximab and CD20 mutation].
    Terui Y; Hatake K
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():416-23. PubMed ID: 17474440
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma.
    Hofer S; Hunziker S; Dirnhofer S; Ludwig C
    Br J Haematol; 2003 Aug; 122(4):690-1. PubMed ID: 12899729
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
    Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.
    Treon SP; Anderson KC
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):79-85. PubMed ID: 11226004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab not affected by statins?
    Pharmacogenomics; 2009 Feb; 10(2):259. PubMed ID: 19207027
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term response to maintenance treatment with rituximab in CD20(+) multiple myeloma.
    Ohno H
    Leuk Lymphoma; 2010 Nov; 51(11):2144-6. PubMed ID: 20807088
    [No Abstract]   [Full Text] [Related]  

  • 15. Selective loss of lymphoid component simulating myeloma in lymphoplasmacytic lymphoma treated with rituximab.
    O'Connor SR; Rana SK
    Br J Haematol; 2013 May; 161(4):460. PubMed ID: 23530469
    [No Abstract]   [Full Text] [Related]  

  • 16. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
    Treon SP; Pilarski LM; Belch AR; Kelliher A; Preffer FI; Shima Y; Mitsiades CS; Mitsiades NS; Szczepek AJ; Ellman L; Harmon D; Grossbard ML; Anderson KC
    J Immunother; 2002; 25(1):72-81. PubMed ID: 11924912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pure red cell aplasia associated with CD20+ myeloma: complete remission with rituximab.
    So CC; Choi WW; Kwong YL
    Ann Hematol; 2013 Oct; 92(10):1425-6. PubMed ID: 23494205
    [No Abstract]   [Full Text] [Related]  

  • 19. Toward an effective targeted chemotherapy for multiple myeloma.
    Polson AG; Sliwkowski MX
    Clin Cancer Res; 2009 Jun; 15(12):3906-7. PubMed ID: 19509145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999.
    Grillo-López AJ; Kunkel L
    Clin Cancer Res; 2000 Jan; 6(1):317-8. PubMed ID: 10656464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.